These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18018484)

  • 61. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
    Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
    Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 63.
    Nagoshi E
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373150
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2007; (72):113-20. PubMed ID: 17982884
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dementia in Parkinson's disease. Morphometric data.
    Duyckaerts C; Gaspar P; Costa C; Bonnet AM; Hauw JJ
    Adv Neurol; 1993; 60():447-55. PubMed ID: 8420169
    [No Abstract]   [Full Text] [Related]  

  • 66. What have we learned from Drosophila models of Parkinson's disease?
    Guo M
    Prog Brain Res; 2010; 184():3-16. PubMed ID: 20887867
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.
    Maetzler W; Berg D; Schalamberidze N; Melms A; Schott K; Mueller JC; Liaw L; Gasser T; Nitsch C
    Neurobiol Dis; 2007 Mar; 25(3):473-82. PubMed ID: 17188882
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines.
    Nagatsu T; Sawada M
    Cell Mol Neurobiol; 2006; 26(4-6):781-802. PubMed ID: 16823625
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effects of striatal silent lacunar infarction on the substantia nigra and movement disorders in Parkinson's disease: A follow-up study.
    Zhang G; Zhang C; Zhang Y; Wang Y; Nie K; Zhang B; Xie H; Lu J; Wang L
    Parkinsonism Relat Disord; 2017 Oct; 43():33-37. PubMed ID: 28688982
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Animal models of PD: pieces of the same puzzle?
    Dawson T; Mandir A; Lee M
    Neuron; 2002 Jul; 35(2):219-22. PubMed ID: 12160740
    [TBL] [Abstract][Full Text] [Related]  

  • 71. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cell transplantation in the damaged adult brain.
    Jaber M; Benoit-Marand M; Prestoz L; Gaillard A
    Rev Neurol (Paris); 2013 Nov; 169(11):838-43. PubMed ID: 24112517
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [GBA mutations and Parkinson's disease].
    Wang DX; Xie JX; Song N
    Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of Aging in the Striatum and Substantia Nigra of a Parkinson's Disease Animal Model.
    Ureshino RP; Costa AJ; Erustes AG; Pereira GJDS; Sinigaglia-Coimbra R; Smaili SS
    Toxicol Pathol; 2018 Apr; 46(3):348-358. PubMed ID: 29683090
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease.
    Barzilai A; Melamed E
    Trends Mol Med; 2003 Mar; 9(3):126-32. PubMed ID: 12657434
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
    Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.
    Greffard S; Verny M; Bonnet AM; Seilhean D; Hauw JJ; Duyckaerts C
    Neurobiol Aging; 2010 Jan; 31(1):99-103. PubMed ID: 18457903
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Parkinson disease.
    Balestrino R; Schapira AHV
    Eur J Neurol; 2020 Jan; 27(1):27-42. PubMed ID: 31631455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.